Núria Farré1, Júlia Aranyó2, Cristina Enjuanes3, José María Verdú-Rotellar4, Sonia Ruiz1, Gina Gonzalez-Robledo1, Oona Meroño1, Marta de Ramon5, Pedro Moliner3, Jordi Bruguera1, Josep Comin-Colet6. 1. Heart Failure Programme, Department of Cardiology, Hospital del Mar, Barcelona, Spain; Heart Diseases Biomedical Research Group, Program of Research in Inflammatory and Cardiovascular Disorders, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 2. Heart Failure Programme, Department of Cardiology, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, School of Medicine, Spain; Universitat Autònoma de Barcelona, School of Medicine, Spain. 3. Heart Failure Programme, Department of Cardiology, Hospital del Mar, Barcelona, Spain; Heart Diseases Biomedical Research Group, Program of Research in Inflammatory and Cardiovascular Disorders, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra, School of Medicine, Spain; Universitat Autònoma de Barcelona, School of Medicine, Spain. 4. Heart Diseases Biomedical Research Group, Program of Research in Inflammatory and Cardiovascular Disorders, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra, School of Medicine, Spain; Universitat Autònoma de Barcelona, School of Medicine, Spain; Jordi Gol Primary Care Research Institute. Catalan Institute of Heath, Barcelona (Spain). 5. Laboratori de Referència de Catalunya, Spain. 6. Heart Failure Programme, Department of Cardiology, Hospital del Mar, Barcelona, Spain; Heart Diseases Biomedical Research Group, Program of Research in Inflammatory and Cardiovascular Disorders, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra, School of Medicine, Spain; Universitat Autònoma de Barcelona, School of Medicine, Spain. Electronic address: josepcomin@gmail.com.
Abstract
BACKGROUND: Obese patients with chronic Heart Failure (HF) have better outcome than their lean counterparts, although little is known about the pathophysiology of this obesity paradox. Our aim was to evaluate the hypothesis that patients with chronic HF and obesity (defined as body mass index (BMI)≥30kg/m(2)), may have an attenuated neurohormonal activation in comparison with non-obese patients. METHODS AND RESULTS: The present study is the post-hoc analysis of a cohort of 742 chronic HF patients from a single-center study evaluating sympathetic activation by measuring baseline levels of norepinephrine (NE). Obesity was present in 33% of patients. Higher BMI and obesity were significantly associated with lower NE levels in multivariable linear regression models adjusted for covariates (p<0.001). Addition to NE in multivariate Cox proportional hazard models attenuated the prognostic impact of BMI in terms of outcomes. Finally, when we explored the prognosis impact of raised NE levels (>70th percentile) carrying out a separate analysis in obese and non-obese patients we found that in both groups NE remained a significant independent predictor of poorer outcomes, despite the lower NE levels in patients with chronic HF and obesity: all-cause mortality hazard ratio=2.37 (95% confidence interval, 1.14-4.94) and hazard ratio=1.59 (95% confidence interval, 1.05-2.4) in obese and non-obese respectively; and cardiovascular mortality hazard ratio=3.08 (95% confidence interval, 1.05-9.01) in obese patients and hazard ratio=2.08 (95% confidence interval, 1.42-3.05) in non-obese patients. CONCLUSION: Patients with chronic HF and obesity have significantly lower sympathetic activation. This finding may partially explain the obesity paradox described in chronic HF patients.
BACKGROUND:Obesepatients with chronic Heart Failure (HF) have better outcome than their lean counterparts, although little is known about the pathophysiology of this obesity paradox. Our aim was to evaluate the hypothesis that patients with chronic HF and obesity (defined as body mass index (BMI)≥30kg/m(2)), may have an attenuated neurohormonal activation in comparison with non-obesepatients. METHODS AND RESULTS: The present study is the post-hoc analysis of a cohort of 742 chronic HF patients from a single-center study evaluating sympathetic activation by measuring baseline levels of norepinephrine (NE). Obesity was present in 33% of patients. Higher BMI and obesity were significantly associated with lower NE levels in multivariable linear regression models adjusted for covariates (p<0.001). Addition to NE in multivariate Cox proportional hazard models attenuated the prognostic impact of BMI in terms of outcomes. Finally, when we explored the prognosis impact of raised NE levels (>70th percentile) carrying out a separate analysis in obese and non-obesepatients we found that in both groups NE remained a significant independent predictor of poorer outcomes, despite the lower NE levels in patients with chronic HF and obesity: all-cause mortality hazard ratio=2.37 (95% confidence interval, 1.14-4.94) and hazard ratio=1.59 (95% confidence interval, 1.05-2.4) in obese and non-obese respectively; and cardiovascular mortality hazard ratio=3.08 (95% confidence interval, 1.05-9.01) in obesepatients and hazard ratio=2.08 (95% confidence interval, 1.42-3.05) in non-obesepatients. CONCLUSION:Patients with chronic HF and obesity have significantly lower sympathetic activation. This finding may partially explain the obesity paradox described in chronic HF patients.
Authors: Matthew A Carson; Joanne Reid; Loreena Hill; Lana Dixon; Patrick Donnelly; Paul Slater; Alyson Hill; Susan E Piper; Theresa A McDonagh; Donna Fitzsimons Journal: Palliat Med Date: 2022-06-21 Impact factor: 5.713
Authors: Rosa M Agra-Bermejo; Rocio Gonzalez-Ferreiro; J Nicolos Lopez-Canoa; Alfonso Varela-Roman; Ines Gomez-Otero; Sonia Eiras; José R González-Juanatey Journal: J Cardiovasc Transl Res Date: 2018-10-23 Impact factor: 4.132
Authors: Suriya Prausmüller; Gregor Heitzinger; Noemi Pavo; Georg Spinka; Georg Goliasch; Henrike Arfsten; Cornelia Gabler; Guido Strunk; Christian Hengstenberg; Martin Hülsmann; Philipp E Bartko Journal: J Cachexia Sarcopenia Muscle Date: 2022-03-29 Impact factor: 12.063